Skip to content

Impact of Aspiration Thrombectomy During Carotid Stenting

Impact of Aspiration Thrombectomy During Carotid Stenting on New Ischemic Lesions Identified by Diffusion-Weighted Magnetic Resonance Imaging

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01550835
Enrollment
80
Registered
2012-03-12
Start date
2012-02-29
Completion date
Unknown
Last updated
2015-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Artery Stenosis

Keywords

Symptomatic carotid artery stenosis

Brief summary

The purpose of this study is to determine whether aspiration thrombectomy following carotid stent deployment will reduce the number of procedure related signals as identified by diffusion weighted MRI of the brain.

Detailed description

Studies have demonstrated that carotid artery stenting is a safe and effective alternative to carotid endarterectomy for high or standard risk patients with symptomatic stenosis. Despite the routine use of embolic protection devices, numerous studies have shown that carotid stenting is associated with a higher degree of intracranial emboli by diffusion-weighted MRI of the brain. A potential solution to minimize this effect is the use of aspiration prior to distal embolic protection removal.

Interventions

DEVICEEmboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)

Standard of care use of an embolic protection device

Sponsors

Abbott Medical Devices
CollaboratorINDUSTRY
Helen Kay Foundation
CollaboratorUNKNOWN
Northern Michigan Hospital Foundation's Louis A. and Sally Cannon
CollaboratorUNKNOWN
Fogarty Clinical Research Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ICA stenosis greater than 50 percent by carotid angiography * Documented hemispheric ischemic stroke, TIA, amaurosis fugax, or retinal stroke in the last six months ipsilateral to the stented lesion

Exclusion criteria

* Subject less than 40 years of age * Pregnant subjects * Asymptomatic carotid stenosis * Total occlusion of target carotid artery * Inability to deploy distal protection device or stent in target vessel * Allergy to both aspirin and approved thienopyridine anti-platelet drugs (clopidogrel/ticlopidine) * Multiple carotid stenoses in same vessel that cannot be covered by single stent * Ipsilateral intracranial stenosis requiring treatment * Isolated common carotid stenosis * Stenosis less than 50 percent by angiography * Chronic or paroxysmal atrial fibrillation not treated with warfarin or dabigatran. * Life expectancy less than 30 days * Active bleeding diathesis * Suspected Myocardial Infarction within 72 hours prior to carotid stenting * Presence of intracranial tumor arteriovenous malformations or aneurysm requiring treatment * Inability to undergo DWMRI * Unwillingness to participate or provide consent * Subjects using a legally authorized representative for consent for participation * Concurrently enrolled in another study * Stroke, TIA, amaurosis fugax ipsilateral to the treated lesion more than 6 months from randomization * Occlusive or critical ilio-femoral disease that precludes safe femoral access to the aortic arch * Severe atherosclerosis of the aortic arch or origin of the innominate or common carotid arteries * Prior large stroke, multiple lacunar infarcts, or dementia * Stenosis that contain visible thrombus

Design outcomes

Primary

MeasureTime frameDescription
Number of new, ischemic foci18-48 hours post procedureFoci of restricted diffusion will be classified by their number, location, and size

Secondary

MeasureTime frameDescription
Ischemic zone area18-48 hours post stentingMaximum size of new, ipsilateral,ischemic foci on post-carotid stenting diffusion-weighted MRI of the brain

Countries

United States

Contacts

Primary ContactBetty deBettencourt, RN
betty.debettencourt@fogartyinstitute.org650-962-4566

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026